Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
Status:
Terminated
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the safety of the investigational drug called
dimethylfumarate (DMF). DMF is a type of drug called an immunomodulatory drug. This drug is
approved by the United States (U.S.) Food and Drug Administration (FDA) as a treatment for
patient with multiple sclerosis.
Although there is evidence from tests on laboratory animals that DMF can decrease the number
of CLL cells, we do not know if this will work in humans with CLL. This drug will be given to
humans with CLL for the first time in this study. Therefore, the goal of this study is to see
if DMF is safe and tolerable in study participants. Participants will be evaluated to find
out what effects (good and bad) DMF has on the body and see how long the drug stays in the
body.